Elpis Biopharmaceuticals has signed an MoU with the National Cancer Centre Singapore. The collaboration focuses on advancing clinically validated armoured CAR technologies into first-in-human trials in Singapore and accelerating translational research from bench-to-bedside.
Daniel Tan | 28/07/2025 | By Mrinmoy Dey | 276
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy